4547:TYO
Kissei Pharmaceutical Co Ltd
4 030,00 JPY
arrow_upward
+0,62%(+25,00) 1D
8 სექ, 15:30:00 GMT+9 · JPY
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
4 000 JPY
High
4 050 JPY
Low
3 990 JPY
Mkt. cap
187,56 მლრ.
Avg. vol.
70,30 ათ.
Volume
40,60 ათ.
Dividend
2,98%
Quarterly dividend
30 JPY
Ex-dividend date
29 სექ. 2026
P/E ratio
11,95
52-wk high
5 040 JPY
52-wk low
3 500 JPY
EPS
337 JPY
Shares outstanding
46,72 მლნ.
No. of employees
2 ათ.
Open
4 000 JPY
High
4 050 JPY
Low
3 990 JPY
Mkt. cap
187,56 მლრ.
Avg. vol.
70,30 ათ.
Volume
40,60 ათ.
Dividend
2,98%
Quarterly dividend
30 JPY
Ex-dividend date
29 სექ. 2026
P/E ratio
11,95
52-wk high
5 040 JPY
52-wk low
3 500 JPY
EPS
337 JPY
Shares outstanding
46,72 მლნ.
No. of employees
2 ათ.
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOმუცუო კანზავა
Employees1,79 ათ.
Founded9 აგვ. 1946
HeadquartersMatsumoto, Nagano, იაპონია
SectorPharmaceutical industry
Websitekissei.co.jp